Bioxcel Therapeutics Inc (BTAI) just unveiled an update.
BioXcel Therapeutics, Inc. has unveiled an updated corporate overview and its business strategy, with a focus on its upcoming SERENITY At-Home Phase 3 trial. This pivotal study will explore the effectiveness and safety of BXCL501, an investigational treatment for agitation in bipolar and schizophrenia patients, in a home environment based on recent FDA feedback. The trial aims to enroll around 200 patients, assessing both safety and exploratory efficacy endpoints over 12 weeks. Additionally, a smaller study will examine the correlation between patient and professional efficacy assessments. BioXcel’s forward-looking statements highlight the company’s aspirations and ongoing research, although they come with the usual caveats of uncertainty inherent in clinical development.
For an in-depth examination of BTAI stock, go to TipRanks’ Stock Analysis page.
